Stock listing
Chimeric Therapeutics Limited
Selected listing: CHM · ASX · AUD · AU
Chimeric Therapeutics Limited (ASX:CHM), Health Technology. Latest release Aug 18, 2026: CHM ceases enrolment in Phase 1 trial and Company update.
- Ticker
- ASX:CHM
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
About Chimeric Therapeutics Limited
The company focuses on developing innovative therapies in the field of cell and gene therapy. Chimeric Therapeutics aims to address significant unmet medical needs through its advanced research and development initiatives.
Latest news from Chimeric Therapeutics Limited
CHM ceases enrolment in Phase 1 trial and Company update
August 18, 2026
Chimeric receives $1.62M advance on FY26 R&D tax incentive
July 29, 2026
CHM CDH17 Phase 1 clinical trial update - New DL 3 data
July 15, 2026
Appointment of Financial Adviser for Strategic Review
June 30, 2026
CHM announces positive Phase 1/2 data at ASCO
May 31, 2026
Research Chimeric Therapeutics Limited
Chimeric Therapeutics Limited company profile
View the public company page for Chimeric Therapeutics Limited on 6ix.
Chimeric Therapeutics Limited news
Read company news and market updates connected to Chimeric Therapeutics Limited.
Chimeric Therapeutics Limited investor events
Find investor webinars, events, and replay context for Chimeric Therapeutics Limited.